These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 16312841

  • 1. Clinical pharmacology of cisplatin after intraperitoneal administration in patients with malignant ascites.
    Fracasso ME, Apostoli P, Benoni G, Bonetti A, Griso C, Leone R.
    J Chemother; 1989 Jul; 1(4 Suppl):1218-9. PubMed ID: 16312841
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
    Han GR, Cai GF.
    Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD, Sarantopoulos J, Calvo E, Chu QS, Greene D, Nathan FE, Petrone ME, Tolcher AW, Papadopoulos KP.
    Clin Cancer Res; 2009 Jun 01; 15(11):3866-71. PubMed ID: 19458055
    [Abstract] [Full Text] [Related]

  • 11. [1st experiences in the treatment of ovarian tumors with Peptichemio].
    Natale N, Mangioni C, Remotti G.
    Minerva Med; 1974 May 02; 65(33):1805-10. PubMed ID: 4367233
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
    Tkalia IG, Vorobyova LI, Grabovoy AN, Svintsitsky VS, Tarasova TO.
    Exp Oncol; 2015 Mar 02; 37(1):30-5. PubMed ID: 25804228
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antiemetic therapy in patients treated with cisplatin chemotherapy.
    Roila F, Basurto C, Bracarda S, Del Favero A, Tonato M.
    J Chemother; 1989 Jul 02; 1(4 Suppl):1281-5. PubMed ID: 16312866
    [No Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.
    Royer B, Jullien V, Guardiola E, Heyd B, Chauffert B, Kantelip JP, Pivot X.
    Clin Pharmacokinet; 2009 Jul 02; 48(3):169-80. PubMed ID: 19385710
    [Abstract] [Full Text] [Related]

  • 17. [The pharmacokinetics and clinical toxicities following intraperitoneal infusion of cis-diamminedichloroplatinum (II) with simultaneous sodium thiosulfate rescue in patients with ovarian cancer].
    Takizawa K, Ino Y, Isono T, Sato M, Iguchi T, Takeda Y.
    Nihon Gan Chiryo Gakkai Shi; 1988 Jul 20; 23(7):1483-90. PubMed ID: 3183457
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
    Kim HS, Kang SB, Seo SS, Han SS, Kim JW, Park NH, Kang SB, Lee HP, Song YS.
    Ann N Y Acad Sci; 2009 Aug 20; 1171():627-34. PubMed ID: 19723113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.